BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 18, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Sutent sunitinib regulatory update

FDA's Oncologic Drugs Advisory Committee (ODAC) voted 8-2 that Pfizer's Sutent sunitinib had a favorable benefit-risk profile to treat...

Read the full 74 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >